Erectile Dysfunction Drugs Market Size, Share, Analysis, Trends, Growth, 2032

Erectile Dysfunction Drugs Industry Prospective:

The global erectile dysfunction drugs market reached nearly USD 3.64 billion in 2021 and is projected to expand with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period to grow by about USD 5.94 billion by 2028. This global report is packed with key drivers and opportunities that can spur market growth during the forecast period. Along with this detailed study on major market, restrains & challenges and their cumulative impact is also discussed in the report. The report also covers all the regional market studies with revenue and market share for major countries.

Request Free Sample

Erectile Dysfunction Drugs Market: Overview

Erectile dysfunction is the incapability to attain and maintain a hard erection for sexual activity. Having problems with erection isn't usually a reason for fear. However, if erectile dysfunction is a long-term condition, it can create stress, lower self-esteem, and lead to marital issues. Problems obtaining or maintaining an erection can be a symptom of a more serious underlying health issue, as well as a possible risk for cardiovascular disease. To treat such conditions several drugs are available on the market that can help to maintain the erection during sexual intercourse. With a change in lifestyle and increased stress conditions need for these drugs is on the rise.

Request Free Sample

Erectile Dysfunction Drugs Market: Growth Drivers

Growth in embracing poor lifestyle choices may boost the market growth over the forecast period.

With the surge in the adoption of a bad lifestyle, diabetes, obesity, and cardiovascular disease are on the rise, which in turn leads to problems like ED as people become older. The present lifestyle of youth in many emerging countries is very stressful resulting in increased alcoholism, smoking, and fast food or ready-to-eat food consumption. Due to these factors, overall health and fitness are getting compromised which in turn increases the chances of ED. Furthermore, as the senior population grows, so does the number of ED patients, which is a significant driver of the global erectile dysfunction drugs market throughout the projection period.

Erectile Dysfunction Drugs Market: Restraints

Low awareness and side effects associated with erectile dysfunction drugs may hinder the market growth.

Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries. This is mainly due to less knowledge about these types of medication, low buying power, and less willingness to adopt such kinds of medications in lifestyle. Furthermore, side effects associated with these drugs such as headache, upset stomach, flushing, nasal congestion, vision problems, dizziness, diarrhea, and rash also contribute to the slow growth of the market.

Erectile Dysfunction Drugs Market: Opportunities

Increased pharmaceutical manufacturing in emerging countries is likely to offer better growth opportunities for market expansion.

In the last couple of years, major and emerging brands in pharmaceutical industries have increased their investments in emerging countries like India, China, Africa, and major Middle East countries. This has significantly lowered the cost of medicine along with the supply and the distribution of drugs within the countries which is expected to offer significance. Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market.

Erectile Dysfunction Drugs Market: Report Scope

Erectile Dysfunction Drugs Market: Challenges.

An increase in the availability of counterfeit erectile dysfunction medicines poses a major challenge to the market expansion.

The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market. Consumers typically choose lower-cost generic erectile dysfunction pills over more expensive blockbuster kinds due to the profitable marketing of counterfeit erectile dysfunction drugs at considerably cheaper prices than either patented or generic pharmaceuticals. Aside from that, when patents on blockbuster pharmaceuticals expire, new generic equivalents are entering the market, generally at inexpensive rates.

Erectile Dysfunction Drugs Market: Segmentation

The global erectile dysfunction market is categorized based on therapeutics and region.

By therapeutics, the global erectile dysfunction market is bifurcated into Existing drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, and Melanocortin Activators.

Recent Developments

May 2020, Metuchen Pharmaceuticals, L.L.C., a privately owned biopharmaceutical aimed at defining, developing, gaining, and commercializing revolutionary therapeutics for male sexual health conditions, and Neurotrope, Inc. ("Neurotrope") officially revealed that the two firms have decided to enter into a concise merger agreement within which Metuchen and Neurotrope, Inc. will unite in an all-stock purchase arising in a newly formed partnership firm ("Petros"). Petros is anticipated to become a Nasdaq-listed corporation specializing in men's health.

Erectile Dysfunction Drugs Market: Regional Landscape

North America is projected to lead the global market over the forecast period.

North America is likely to dominate the global erectile dysfunction drugs market. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. When the last of the baby boom cohorts reach 65, the number of older individuals is predicted to climb by roughly 18 million between 2020 and 2030. Because ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it. The domination of these countries is due to the availability of numerous ED medicines by OTC and internet outlets. The National Institute of Diabetes and Digestive and Kidney Diseases stated roughly 30 million men in the United States suffer from ED. Furthermore, the United States has the greatest rate of self-reported ED. As a result, rising ED prevalence in the US is likely to fuel market growth throughout the projection period.

Erectile Dysfunction Drugs Market: Competitive Landscape

Major players operating in the global erectile dysfunction drugs market include

• Eli Lilly & Co.
• Pfizer
• Dong-A Pharmaceutical Co. Ltd
• Bayer AG
• Meda Pharmaceuticals
• Vivus Inc.
• Apricus Biosciences.

Global erectile dysfunction drugs market is segmented as follows:

By Therapeutics

• Existing drugs
• Tadalafil
• Sildenafil Citrate Vardenafil
• Udenafil
• Stendra/Spedra
• Lodenafil Carbonate
• Mirodenafil Pipeline drugs
• Apomorphine
• Alprostadil
• Topiglan
• Gene Therapy
• Melanocortin Activators

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa